Adjuvant Immunotherapy Ups Survival in dMMR Colon Cancer

(MedPage Today) -- CHICAGO -- The risk of recurrence or death after surgery for deficient mismatch repair (dMMR) colon cancer decreased by 50% in patients who received immunotherapy in addition to adjuvant chemotherapy, a large randomized trial...